J. RandolphHechtMD

Gastrointestinal Cancer

Professor of Clinical Medicine; Director UCLA GI Oncology Program

Dr. Hecht is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
200 Medical 420 530 120 Plz
# 365
Los Angeles, CA 90095
Phone+1 310-586-2097

Fax+1 310-586-0841

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1997
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 1988 - 1991
University of ChicagoFellowship, Research, 1987 - 1988
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
Eastern Virginia Medical SchoolClass of 1984

A Study of SGN-EGFRd2 in Advanced Solid Tumors Start of enrollment: 2023 Nov 14
Recruiting
Phase 1
Roles: Contact, Principal Investigator

PubMed

2731 citations
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Cl...
Malcolm J. Moore, David Goldstein, John T. Hamm, Arie Figer, J. R. Hecht
Journal of Clinical Oncology. 2007-05-20
826 citations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi Jen Chen
Journal of the National Comprehensive Cancer Network. 2021-03-02
377 citations
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, Josep Tabernero, Stephen Clarke
The Lancet. Oncology. 2012-12-01

Lectures

A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in c...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018